Display options
Cite
Carrascal-Laso L, Franco-Martín MÁ, García-Berrocal MB, et al. Application of a Pharmacogenetics-Based Precision Medicine Model (5SPM) to Psychotic Patients That Presented Poor Response to Neuroleptic Therapy. J Pers Med. 2020;10(4)doi: 10.3390/jpm10040289.
Carrascal-Laso, L., Franco-Martín, M. �. �., García-Berrocal, M. B., Marcos-Vadillo, E., Sánchez-Iglesias, S., Lorenzo, C., Sánchez-Martín, A., Ramos-Gallego, I., García-Salgado, M. J., Isidoro-García, M., Chu, S. L., Schlegel, R., Quek, F., & Christy, A. (2020). Application of a Pharmacogenetics-Based Precision Medicine Model (5SPM) to Psychotic Patients That Presented Poor Response to Neuroleptic Therapy. Journal of personalized medicine, 10(4), . https://doi.org/10.3390/jpm10040289
Carrascal-Laso, Lorena, et al. "Application of a Pharmacogenetics-Based Precision Medicine Model (5SPM) to Psychotic Patients That Presented Poor Response to Neuroleptic Therapy." Journal of personalized medicine vol. 10,4 (2020). doi: https://doi.org/10.3390/jpm10040289
Carrascal-Laso L, Franco-Martín MÁ, García-Berrocal MB, Marcos-Vadillo E, Sánchez-Iglesias S, Lorenzo C, Sánchez-Martín A, Ramos-Gallego I, García-Salgado MJ, Isidoro-García M, Chu SL, Schlegel R, Quek F, Christy A. Application of a Pharmacogenetics-Based Precision Medicine Model (5SPM) to Psychotic Patients That Presented Poor Response to Neuroleptic Therapy. J Pers Med. 2020 Dec 18;10(4). doi: 10.3390/jpm10040289. PMID: 33352925; PMCID: PMC7767089.
Copy Download .nbib Format: NLM
Share it on

J Pers Med. 2020 Dec 18;10(4). doi: 10.3390/jpm10040289.

Application of a Pharmacogenetics-Based Precision Medicine Model (5SPM) to Psychotic Patients That Presented Poor Response to Neuroleptic Therapy.

Journal of personalized medicine

Lorena Carrascal-Laso, Manuel Ángel Franco-Martín, María Belén García-Berrocal, Elena Marcos-Vadillo, Santiago Sánchez-Iglesias, Carolina Lorenzo, Almudena Sánchez-Martín, Ignacio Ramos-Gallego, M Jesús García-Salgado, María Isidoro-García, Chu, Schlegel, Quek, Christy

Affiliations

  1. Servicio de Psiquiatría, Hospital Provincial de Zamora, IBSAL, 49071 Zamora, Spain.
  2. Farmacogenética y Medicina de Precisión, Servicio de Bioquímica, Hospital Universitario de Salamanca, IBSAL, 37007 Salamanca, Spain.
  3. Servicio de Psiquiatría, Hospital Universitario de Salamanca, IBSAL, 37007 Salamanca, Spain.
  4. Pharmacogenetics Unit, Pharmacy Department, University Hospital Virgen de las Nieves, UGC Provincial de Farmacia de Granada, Avda, Fuerzas Armadas, 18014 Granada, Spain.
  5. Departamento de Fisiología y Farmacología, Universidad de Salamanca, 37007 Salamanca, Spain.
  6. Departamento de Medicina, Universidad de Salamanca, 37007 Salamanca, Spain.

PMID: 33352925 PMCID: PMC7767089 DOI: 10.3390/jpm10040289

Abstract

Antipsychotics are the keystone of the treatment of severe and prolonged mental disorders. However, there are many risks associated with these drugs and not all patients undergo full therapeutic profit from them. The application of the 5 Step Precision Medicine model(5SPM), based on the analysis of the pharmacogenetic profile of each patient, could be a helpful tool to solve many of the problematics traditionally associated with the neuroleptic treatment. In order to solve this question, a cohort of psychotic patients that showed poor clinical evolution was analyzed. After evaluating the relationship between the prescribed treatment and pharmacogenetic profile of each patient, a great number of pharmacological interactions and pharmacogenetical conflicts were found. After reconsidering the treatment of the conflictive cases, patients showed a substantial reduction on mean daily doses and polytherapy cases, which may cause less risk of adverse effects, greater adherence, and a reduction on economic costs.

Keywords: antipsychotic agents; cytochrome P-450 enzyme system; pharmacogenetics; precision medicine; psychotic disorders

References

  1. Pharmacogenomics J. 2009 Dec;9(6):404-10 - PubMed
  2. Eur J Clin Pharmacol. 2016 Feb;72(2):175-84 - PubMed
  3. J Clin Psychopharmacol. 2013 Oct;33(5):593-9 - PubMed
  4. Lancet Psychiatry. 2019 May;6(5):418-426 - PubMed
  5. Eur Respir J. 2017 Oct 19;50(4): - PubMed
  6. Pharmacogenomics. 2009 Sep;10(9):1457-66 - PubMed
  7. Mol Diagn Ther. 2013 Jun;17(3):165-84 - PubMed
  8. Gen Hosp Psychiatry. 2011 Sep-Oct;33(5):501-8 - PubMed
  9. Front Pharmacol. 2020 Feb 04;10:1669 - PubMed
  10. J Clin Psychiatry. 2015 Sep;76(9):e1159-60 - PubMed
  11. Pharmacogenet Genomics. 2013 May;23(5):279-85 - PubMed
  12. Indian J Psychiatry. 2013 Apr;55(2):207-8 - PubMed
  13. Pharmacopsychiatry. 2014 May;47(3):101-4 - PubMed
  14. Psychiatr Serv. 2019 Aug 1;70(8):650-656 - PubMed
  15. Curr Drug Metab. 2010 Jul;11(6):516-25 - PubMed
  16. Clin Pharmacol Ther. 2018 Mar;103(3):399-401 - PubMed
  17. BMC Med Genet. 2019 Apr 9;20(Suppl 1):47 - PubMed
  18. Pharmacogenomics. 2011 Aug;12(8):1193-211 - PubMed
  19. Psychiatry Clin Neurosci. 2012 Oct;66(6):518-24 - PubMed
  20. Basic Clin Pharmacol Toxicol. 2018 Jun;122(6):596-605 - PubMed
  21. Stud Hist Philos Biol Biomed Sci. 2011 Dec;42(4):443-52 - PubMed
  22. Cold Spring Harb Perspect Med. 2014 Jul 24;4(9):a008581 - PubMed
  23. Xenobiotica. 2020 Jan;50(1):9-18 - PubMed
  24. Br J Clin Pharmacol. 2015 Feb;79(2):222-40 - PubMed
  25. Int J Neuropsychopharmacol. 2020 Feb 1;23(2):125-131 - PubMed
  26. Nucleic Acids Res. 2014 Jan;42(Database issue):D1113-7 - PubMed
  27. Clin Psychopharmacol Neurosci. 2020 Feb 29;18(1):159-163 - PubMed
  28. Gene Ther. 2017 Sep;24(9):551-561 - PubMed
  29. J Clin Psychiatry. 2016;77(suppl 3):1-24 - PubMed
  30. Schizophr Res. 2018 Feb;192:131-136 - PubMed
  31. Basic Clin Pharmacol Toxicol. 2013 Oct;113(4):266-72 - PubMed
  32. Cochrane Database Syst Rev. 2018 May 11;5:CD011883 - PubMed
  33. J Clin Psychopharmacol. 2014 Apr;34(2):256-60 - PubMed
  34. BMJ. 2007 Jan 6;334 Suppl 1:s7 - PubMed
  35. Mol Diagn Ther. 2006;10(3):135-51 - PubMed
  36. Rev Psiquiatr Salud Ment. 2014 Oct-Dec;7(4):166-78 - PubMed
  37. Genome Med. 2016 Dec 19;8(1):134 - PubMed
  38. Asian J Psychiatr. 2020 Jun;51:102022 - PubMed
  39. Curr Drug Metab. 2008 Jun;9(5):410-8 - PubMed
  40. J Clin Psychopharmacol. 2010 Oct;30(5):504-11 - PubMed
  41. J Clin Pharmacol. 1994 Apr;34(4):286-95 - PubMed
  42. Int J Neuropsychopharmacol. 2014 Dec 11;18(5): - PubMed
  43. Br Med Bull. 2015 Jun;114(1):169-79 - PubMed
  44. Schizophr Res. 2013 Sep;149(1-3):1-14 - PubMed

Publication Types